Gallamine Triethiodide

别名: Gallamine Triethochloride; Gallamine Triethiodide; Flaxedil; Tricuran; Gallamoni jodidum; Gallaminii iodidum; Triethyl Iodide, Gallamine; Iodide, Gallamine; Triethyl Iodide, Gallamonium; 加拉碘铵;戈拉碘铵;加拉碘铵 USP标准品;加拉碘铵 标准品;加拉碘铵,BR;三碘季铵酚;2-[2,6-双(2-三乙基铵乙氧基)苯氧基]乙基三乙基铵三碘化物;驰肌碘;驰肌碘,GALLAMINE;碘化浸酚铵;三碘季胺酚
目录号: V1185 纯度: ≥98%
Gallamine Triethiodide (Flaxedil; Tricuran; Gallamoni jodidum; Gallaminii iodidum) 是一种非去极化肌肉松弛剂,是一种有效的心脏选择性胆碱能受体阻滞剂,IC50 为 68.0 ± 8.4 μM。
Gallamine Triethiodide CAS号: 65-29-2
产品类别: AChR Receptor
产品仅用于科学研究,不针对患者销售
规格 价格 库存 数量
250mg
500mg
1g
2g
5g
10g
Other Sizes
点击了解更多
  • 与全球5000+客户建立关系
  • 覆盖全球主要大学、医院、科研院所、生物/制药公司等
  • 产品被大量CNS顶刊文章引用
InvivoChem产品被CNS等顶刊论文引用
纯度/质量控制文件

纯度: ≥98%

产品描述
Gallamine Triethiodide (Flaxedil; Tricuran; Gallamoni jodidum; Gallaminii iodidum) 是一种非去极化肌肉松弛剂,是一种有效的心脏选择性胆碱能受体阻滞剂,IC50 为 68.0 ± 8.4 μM。具体而言,Gallamine Triethiodide 是一种 mAChR M2 拮抗剂,具有显着的心脏选择性。它通过与肌肉中的胆碱能受体位点结合并竞争性阻断乙酰胆碱的递质作用来发挥作用。它是一种合成的非去极化阻断药物。三硫碘化镓胺的作用与筒箭毒碱类似,但这种药物会阻断心脏迷走神经,可能导致窦性心动过速,偶尔还会导致高血压和心输出量增加。
生物活性&实验参考方法
药代性质 (ADME/PK)
Absorption, Distribution and Excretion
STUDIES HAVE DEMONSTRATED THAT GALLAMINE IS EXCRETED IN DOG URINE AT RATE FASTER THAN OTHER MUSCLE RELAXANTS. .../IT/ DID NOT CROSS BLOOD-CEREBROSPINAL FLUID BARRIER. OTHER STUDIES...HAVE DETECTED GALLAMINE IN CEREBROSPINAL FLUID IN CONCN APPROACHING THOSE IN PLASMA DURING 1ST HR AFTER IV INJECTION. /GALLAMINE/
GALLAMINE IS ELIMINATED MAINLY BY RENAL EXCRETION...
... GALLAMINE CROSSES PLACENTAL BARRIER ...
TRACE AMT OF GALLAMINE APPEARS IN FETUS 3 MIN AFTER ADMIN. /GALLAMINE, FROM TABLE/
For more Absorption, Distribution and Excretion (Complete) data for GALLAMINE TRIETHIODIDE (6 total), please visit the HSDB record page.
Metabolism / Metabolites
.../GALLAMINE/ IS UNMETABOLIZED. /GALLAMINE/
Biological Half-Life
135 minutes /From table/
毒性/毒理 (Toxicokinetics/TK)
Interactions
IN ANESTHETIZED PT, IV ADMIN OF DIAZEPAM MAY INCR INTENSITY & PROLONG DURATION OF NEUROMUSCULAR BLOCKADE PRODUCED BY GALLAMINE TRIETHIODIDE. CLINICAL REPORTS...ARE CONFLICTING.../&/ THERE ARE INSUFFICIENT DATA TO EXPLAIN POSSIBLE MECHANISM FOR GALLAMINE TRIETHIODIDE-DIAZEPAM INTERACTION.
NEUROMUSCULAR BLOCKADE PRODUCED BY TUBOCURARINE WAS PROLONGED IN TWO THYROTOXIC PT RECEIVING HIGH DOSES (120 MG/DAY FOR 14 DAYS) OF PROPRANOLOL. ... ALTHOUGH THERE IS NO DOCUMENTATION, THE NONDEPOLARIZING MUSCLE RELAXANT GALLAMINE TRIETHIODIDE...ALSO SHOULD INTERACT WITH PROPRANOLOL.
NEOMYCIN &...RELATED ANTIBIOTICS PRODUCE NEUROMUSCULAR TRANSMISSION FAILURE WHICH MAY CAUSE PROLONGED RESP DEPRESSION OR APNEA IN SURGICAL PT TREATED CONCURRENTLY WITH TUBOCURARINE &...NEUROMUSCULAR DEPRESSANTS. ...ADDITIVE NEUROMUSCULAR DEPRESSION.../REPORTED TO OCCUR WITH GALLAMINE TRIETHIODIDE/.
QUINIDINE, ADMIN PARENTERALLY SHORTLY AFTER OR SIMULTANEOUSLY WITH TUBOCURARINE, MAY ENHANCE OR CAUSE RECURRENT NEUROMUSCULAR EFFECTS OF TUBOCURARINE, RESULTING IN PROLONGATION OR INTENSIFICATION OF RESP DEPRESSION & APNEA. ... GALLAMINE TRIETHIODIDE...HAS BEEN SHOWN TO INTERACT WITH QUINIDINE IN ANIMALS.
For more Interactions (Complete) data for GALLAMINE TRIETHIODIDE (25 total), please visit the HSDB record page.
Non-Human Toxicity Values
LD50 Rat ip 23,200 ug/kg
LD50 Rat sc 28,500 ug/kg
LD50 Rat iv 5100 ug/kg
LD50 Rat intraduodenal 380 mg/kg
For more Non-Human Toxicity Values (Complete) data for GALLAMINE TRIETHIODIDE (13 total), please visit the HSDB record page.
参考文献
J Pharmacol Exp Ther.1986 Jan;236(1):219-23.
其他信息
A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of tubocurarine, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)
A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of TUBOCURARINE, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)
Drug Indication
For use as adjuncts to anesthesia to induce skeletal muscle relaxation and to facilitate the management of patients undergoing mechanical ventilation
Mechanism of Action
It competes with acetylcholine (ACh) molecules and binds to muscarinic acetylcholine receptors on the post-synaptic membrane of the motor endplate. It acts by combining with the cholinergic receptor sites in muscle and competitively blocking the transmitter action of acetylcholine. It blocks the action of ACh and prevents activation of the muscle contraction process. It can also act on nicotinic presynaptic acetylcholine receptors which inhibits the release of ACh.
GALLAMINE TRIETHIODIDE...PRODUCES SKELETAL MUSCLE RELAXATION BY COMBINING WITH RECEPTOR SITE AT NEUROMUSCULAR JUNCTION & BLOCKING ACTION OF NEUROTRANSMITTER ACETYLCHOLINE.
IN RAT PHRENIC NERVE-DIAPHRAGM GALLAMINE HAD NO SIGNIFICANT EFFECTS ON ELECTROGENIC PROPERTIES OF EXCITABLE MEMBRANES OF MOTOR NERVE TERMINALS & MUSCLE FIBERS; IT DEPRESSED RESPONSE OF POSTSYNAPTIC RECEPTORS TO ACTION OF ACETYLCHOLINE.
AT NEUROMUSCULAR JUNCTIONS IN MICE AND FROGS, FOLLOWING STEP CHANGES OF MEMBRANE POTENTIAL FROM -70 TO -130 MV, GALLAMINE (5 UMOL) IN THE PRESENCE OF ACETYLCHOLINE (3 UMOL) CAUSED AN INITIAL RAPID DECR IN CURRENT FOLLOWED BY OPENING OF CHANNELS AT A SLOWER RATE THAN WITH ACETYLCHOLINE ALONE. WHEN THE INTERNAL POTENTIAL WAS REDUCED TO -70 MV, THERE WAS A RAPID INCR IN CURRENT AT FIRST, FOLLOWED BY THE USUAL DECR WHICH WAS AGAIN SLOWER THAN NORMAL. THUS, GALLAMINE MAY PRODUCE A POTENTIAL-DEPENDENT BLOCK OF OPEN ION CHANNELS.
Therapeutic Uses
Neuromuscular Nondepolarizing Agents; Nicotinic Antagonists
A NEUROMUSCULAR BLOCKING DRUG SIMILAR IN ITS ACTIONS & USES TO TUBOCURARINE CHLORIDE. ...IN GENERAL, IT HAS VERY LITTLE ACTION ON AUTONOMIC GANGLIA, BUT IT USUALLY BLOCKS CARDIAC VAGUS... IT ALSO DOES NOT RELEASE HISTAMINE /IN LOW DOSES/.
... IT HAS NO PERCEPTIBLE EFFECT ON NEWBORN INFANTS WHEN USUAL DOSES ARE GIVEN FOR CESAREAN SECTION & VAGINAL DELIVERY & TONE OF UTERUS IS NOT AFFECTED.
...HAS BEEN REPORTED TO REDUCE OCULAR PRESSURE SLIGHTLY IN PT.
For more Therapeutic Uses (Complete) data for GALLAMINE TRIETHIODIDE (9 total), please visit the HSDB record page.
Drug Warnings
THE NEUROMUSCULAR BLOCKING AGENTS ARE POTENTIALLY HAZARDOUS DRUGS. ... THEY SHOULD BE ADMINISTERED TO PATIENTS ONLY BY ANESTHESIOLOGISTS & OTHER CLINICIANS WHO HAVE HAD EXTENSIVE TRAINING IN THEIR USE & IN A SETTING WHERE FACILITIES FOR RESPIRATORY & CARDIOVASCULAR RESUSCITATION ARE IMMEDIATELY AT HAND. /NEUROMUSCULAR BLOCKING AGENTS/
IT SHOULD BE USED CAUTIOUSLY IF TACHYCARDIA PREEXISTS. .../SINCE IT/ IS ELIMINATED MAINLY BY RENAL EXCRETION...ITS ACTION MAY BE PROLONGED IF THERE IS RENAL DYSFUNCTION.
... /IT SHOULD NOT/ BE USED IN PT WITH RENAL DISEASE.
CROSS SENSITIVITY BETWEEN ALCURONIUM & D-TUBOCURARINE OCCURS & SIMILAR SITUATION MAY EXIST FOR SUXAMETHONIUM & GALLAMINE.
For more Drug Warnings (Complete) data for GALLAMINE TRIETHIODIDE (6 total), please visit the HSDB record page.
Pharmacodynamics
Gallamine Triethiodide is a nondepolarizing neuromuscular blocking drug (NDMRD) used as an adjunct to anesthesia to induce skeletal muscle relaxation. The actions of gallamine triethiodide are similar to those of tubocurarine, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. Muscle groups differ in their sensitivity to these types of relaxants with ocular muscles (controlling eyelids) being most sensitive, followed by the muscles of the neck, jaw, limbs and then abdomen. The diaphragm is the least sensitive muscle to NDMRDs. Although the nondepolarizing neuromuscular blocking drugs do not have the same adverse effects as succinylcholine, their onset of action is slower. They also have a longer duration of action, making them more suitable for maintaining neuromuscular relaxation during major surgical procedures.
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C30H60I3N3O3
分子量
891.53
精确质量
891.176
CAS号
65-29-2
相关CAS号
65-29-2
PubChem CID
6172
外观&性状
White to yellow solid powder
密度
0.983g/cm3
沸点
502.6ºC at 760 mmHg
熔点
235ºC (dec.)
闪点
125.9ºC
折射率
1.501
tPSA
27.69
氢键供体(HBD)数目
0
氢键受体(HBA)数目
6
可旋转键数目(RBC)
21
重原子数目
39
分子复杂度/Complexity
489
定义原子立体中心数目
0
InChi Key
REEUVFCVXKWOFE-UHFFFAOYSA-K
InChi Code
InChI=1S/C30H60N3O3.3HI/c1-10-31(11-2,12-3)22-25-34-28-20-19-21-29(35-26-23-32(13-4,14-5)15-6)30(28)36-27-24-33(16-7,17-8)18-9;;;/h19-21H,10-18,22-27H2,1-9H3;3*1H/q+3;;;/p-3
化学名
2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium triiodide
别名
Gallamine Triethochloride; Gallamine Triethiodide; Flaxedil; Tricuran; Gallamoni jodidum; Gallaminii iodidum; Triethyl Iodide, Gallamine; Iodide, Gallamine; Triethyl Iodide, Gallamonium;
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

注意: 请将本产品存放在密封且受保护的环境中(例如氮气保护),避免吸湿/受潮和光照。
运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
DMSO:100 mg/mL (112.2 mM)
Water:<1 mg/mL
Ethanol:100 mg/mL (112.2 mM)
溶解度 (体内实验)
配方 1 中的溶解度: 50 mg/mL (56.08 mM) in PBS (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液; 超声助溶。

请根据您的实验动物和给药方式选择适当的溶解配方/方案:
1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL;

3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果,工作液请现配现用!
6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 1.1217 mL 5.6083 mL 11.2167 mL
5 mM 0.2243 mL 1.1217 mL 2.2433 mL
10 mM 0.1122 mL 0.5608 mL 1.1217 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;

3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);

4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。

计算器

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度,具体如下:

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示:
假如化合物的分子量为350.26 g/mol,在5mL DMSO中制备10mM储备液所需的化合物的质量是多少?
  • 在分子量(MW)框中输入350.26
  • 在“浓度”框中输入10,然后选择正确的单位(mM)
  • 在“体积”框中输入5,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式,您可以计算体积和浓度。

稀释计算器可计算如何稀释已知浓度的储备液。例如,可以输入C1、C2和V2来计算V1,具体如下:

制备25毫升25μM溶液需要多少体积的10 mM储备溶液?
使用方程式C1V1=C2V2,其中C1=10mM,C2=25μM,V2=25 ml,V1未知:
  • 在C1框中输入10,然后选择正确的单位(mM)
  • 在C2框中输入25,然后选择正确的单位(μM)
  • 在V2框中输入25,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案62.5μL(0.1 ml)出现在V1框中
g/mol

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成,具体如下:

注:化学分子式大小写敏感:C12H18N3O4  c12h18n3o4
计算化合物摩尔质量(分子量)的说明:
  • 要计算化合物的分子量 (摩尔质量),请输入化学/分子式,然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义:
  • 分子质量(或分子量)是一种物质的一个分子的质量,用统一的原子质量单位(u)表示。(1u等于碳-12中一个原子质量的1/12)
  • 摩尔质量(摩尔重量)是一摩尔物质的质量,以g/mol表示。
/

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶/难溶于水的化合物),不同的产品和批次配方组成不同,如对配方有疑问,可先联系我们提供正确的体内实验配方。此外,请注意这只是一个配方计算器,而不是特定产品的确切配方。
+
+
+

计算结果:

工作液浓度 mg/mL;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

联系我们